- 英文名称
- Trilaciclib
- 分子式
- C24H30N8O
- 分子量
- 446.55
- 中文别名
- 2'-((5-(4-甲基哌嗪-1-基)吡啶-2-基)氨基)-7',8'-二氢-6'H-吡唑并[环己烷-1,9'-吡嗪并[1',2':1,5]吡咯并[2,3-d]嘧啶]-6'-酮; G1T28; G1T-28; G1T 28; 骨髓保护剂; 化合物 T13202L; 2'-[[5-(4-甲基哌嗪-1-基)吡啶-2-基]氨基}-7',8'-二氢-6'H-螺环[环己烷-1,9'-吡嗪[1',2':1,5]吡咯[2,3-D]嘧啶]-6'-酮; 化合物TRILACICLIB; 2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one; 2'-{[5-(4-Methyl-1-piperazinyl)-2-pyridinyl]amino}-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one; G1T28; 2'-((5-(4-methylpiperazin-1-yl) yridine-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one; Spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one, 7',8'-dihydro-2'-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]-; 2'-[4-(4-methylpiperazin-1-yl)anilino]-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one; G-1T28; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; trilaciclibum; 2'-[[5-(4-Methylpiperazin-1-yl)pyridin-2-yl]amino}-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one; 2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)spiro(7,8-dihydropyrazino(5,6)pyrrolo(1,2-d)pyrimidine-9,1'-cyclohexane)-6-one; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one; Cosela
- 用途
- 曲拉西利是一种静脉注射的短效CDK4/6抑制剂，主要用于与化疗联合治疗小细胞肺癌（SCLC）患者，通过抑制CDK4和CDK6蛋白活性保护骨髓中的造血干/祖细胞，减少化疗引起的骨髓抑制，还可减少化疗的骨髓抑制副作用，可能带来低白血球计数、疲劳、恶心和脱发等副作用。
